查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1580102

道斯症候群市场：依治疗类型、通路划分 - 全球预测 2025-2030 年

Doose Syndrome Market by Treatment Type (Non-Pharmacological Treatments, Pharmacological Treatments), Distribution Channels (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年道斯症候群市场价值为9.9882亿美元，预计到2024年将达到11.3775亿美元，复合年增长率为14.27%，到2030年将达到25.4211亿美元。

道斯综合征，也称为肌阵挛静态癫痫 (MAE)，主要影响儿童，表现为肌阵挛和静态癫痫发作的组合。这种罕见疾病的市场开拓包括开发创新的基因测试、客製化抗癫痫药物以及旨在改善患者预后的客製化治疗。未满足的医疗需求和对特异性治疗的需求不断增长，需要关注未满足的关键字。应用在儿科神经病学、遗传咨询和个人化医疗领域尤其重要，最终用途扩展到医院、专科诊所和研究机构。该市场受到有影响力的成长要素的支持，例如神经遗传学的进步、医疗保健支出的增加和意识的提高。特别是，开发非侵入性诊断工具和先进治疗通讯协定（包括基于大麻二酚的治疗和基因治疗）存在机会。生物技术公司和医疗保健提供者之间的策略伙伴关係可以增加治疗选择并促进新的突破。儘管有这些机会，但挑战仍然存在，包括高昂的研发成本、治疗的潜在副作用以及由于疾病的罕见性而导致大规模临床试验的不足。新治疗方法核准流程的复杂性加剧了这些限制。在创新方面，人工智慧和巨量资料的交叉为预测诊断和治疗效率评估提供了一个有前景的研究领域。在市场研究中，患者登记和纵向研究可以提供有关疾病进展和治疗反应的重要见解。总体而言，KEYWORD市场的特点是其利基性质，这需要製药公司、研究人员和政策制定者共同努力，克服障碍并抓住机会。透过策略性地瞄准这些市场动态，相关人员可以加强开发平臺，并最终改善遭受此挑战的人们的生活品质。

主要市场统计
基准年[2023] 99882万美元
预测年份 [2024] 11.3775亿美元
预测年份 [2030] 25.4211亿美元
复合年增长率（%） 14.27%

市场动态：揭示快速发展的道斯症候群市场的关键市场洞察

道斯综合症市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 政府和非营利组织支持罕见疾病研究和患者照护的努力
    • 采用个人化医疗方法来改善道斯综合症治疗中的患者治疗效果
    • 製药公司与研究机构合作开发道斯综合症标标靶治疗
    • 透过增加针对罕见癫痫症的临床试验的资金来加速新药的发现
  • 市场限制因素
    • 道斯综合症新疗法的严格监管要求和漫长的核准流程阻碍了快速进入市场
    • 关于道斯综合征的全面认识和教育计划尚未普及到基层医疗医生和公众，这阻碍了早期诊断和治疗。
  • 市场进入机会
    • 为受道斯症候群影响的家庭建立专门的病患支援服务和资源
    • 开发综合数位平台来追踪和监测道斯症候群症状和治疗
    • 与医疗保健提供者合作，将道斯综合征治疗通讯协定纳入标准护理中。
  • 市场挑战
    • 道斯综合症治疗的高昂治疗费用和有限的保险范围使许多家庭无法接受。
    • 研究和进行道斯症候群等罕见疾病临床试验的挑战正在减缓新治疗方法的开发。

波特五力：驾驭道斯症候群市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解道斯症候群市场的外部影响

外部宏观环境因素在塑造道斯综合症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解打瞌睡症候群市场的竞争状况

对道斯综合症市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵剂量症候群市场供应商绩效评估

FPNV 定位矩阵是评估道斯症候群市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了打瞌睡症候群市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对道斯综合症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 政府和非营利组织支持罕见疾病研究和患者照护的努力
      • 采用个人化医疗方法可改善道斯综合症治疗中的患者治疗效果
      • 製药公司与研究机构合作开发道斯症候群的标标靶治疗
      • 增加对罕见癫痫临床试验的资助，以加速新药发现
    • 抑制因素
      • 严格的监管要求和新治疗方法漫长的核准流程阻碍了道斯症候群的快速市场进入
      • 基层医疗医生和公众缺乏对道斯综合征的全面认识和教育计划，阻碍了早期诊断和治疗
    • 机会
      • 为受道斯症候群影响的家庭建立专门的病患支援服务和资源
      • 开发一个全面的数位平台来追踪和监测症状和治疗
      • 与医疗保健提供者合作，将道斯综合征治疗通讯协定纳入护理标准
    • 任务
      • 道斯症候群治疗的高昂治疗费用和有限的保险范围使许多家庭无法接受。
      • 研究和进行道斯综合症等罕见疾病临床试验的挑战正在减缓新治疗方法的开发
  • 市场区隔分析
    • 治疗类型：非药物疗法在儿科患者治疗的应用
    • 分销管道：利用零售药房治疗慢性和急性期剂量综合症
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章道斯症候群市场（依治疗类型）

  • 非药物治疗
    • 生酮饮食
    • 迷走神经刺激
  • 药物治疗
    • 抗癫痫药
    • 大麻二酚产品
    • 皮质类固醇
    • 免疫球蛋白

第 7 章道斯症候群市场（依通路）

  • 医院药房
  • 网路药房
  • 零售药房

第八章美洲道斯症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太道斯症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲/中东/非洲道斯症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Jazz Pharmaceuticals 已启动 Epidiolex 治疗 Dawes 症候群的 3 期试验，以减少癫痫发作并扩大其市场份额。
  • 战略分析和建议

公司名单

  • BioMarin Pharmaceutical
  • Cerecor
  • Eisai Co.
  • Greenwich Biosciences
  • GW Pharmaceuticals
  • INSYS Therapeutics
  • Johnson & Johnson
  • Lundbeck
  • Marinus Pharmaceuticals
  • Neurelis
  • Ovid Therapeutics
  • Pfizer
  • PTC Therapeutics
  • Purdue Pharma
  • Sanofi
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Upsher-Smith Laboratories
  • Zogenix
Product Code: MRR-3204321AF692

The Doose Syndrome Market was valued at USD 998.82 million in 2023, expected to reach USD 1,137.75 million in 2024, and is projected to grow at a CAGR of 14.27%, to USD 2,542.11 million by 2030.

Doose Syndrome, also referred to as Myoclonic-Astatic Epilepsy (MAE), primarily affects children and presents with a combination of myoclonic and astatic seizures. The market scope for this rare disorder includes the development of innovative genetic testing, bespoke antiepileptic drugs, and tailored therapeutics aimed at improving patient outcomes. The necessity of focusing on Doose Syndrome stems from unmet medical needs and the increasing demand for specifically-targeted treatments. Applications are particularly pertinent in pediatric neurology, genetic counseling, and personalized medicine sectors, with the end-use scope covering hospitals, specialized clinics, and research institutions. The market is buoyed by influencing growth factors such as advances in neurogenetics, increased healthcare expenditure, and heightened awareness. Opportunities are notably present in the development of non-invasive diagnostic tools and advanced treatment protocols, including cannabidiol-based therapies and gene therapy. Strategic partnerships between biotech firms and healthcare providers can enhance therapeutic options and foster novel breakthroughs. Despite these opportunities, challenges persist, including the high costs of research and development, potential side effects of treatments, and the inadequacy of large-scale clinical trials due to the syndrome's rarity. These constraints are exacerbated by the complexity of regulatory approval processes for new therapies. Regarding innovation, the intersection of artificial intelligence and big data presents promising research areas for predictive diagnostics and treatment efficiency assessment. In conducting market research, leveraging patient registries and longitudinal studies can offer vital insights into disease progression and therapeutic response. Overall, the Doose Syndrome market is characterized by its niche nature, necessitating collaboration among pharmaceutical companies, researchers, and policymakers to overcome barriers and capitalize on opportunities. By strategically targeting these market dynamics, stakeholders can enhance the development pipeline and ultimately improve quality of life for individuals affected by this challenging condition.

KEY MARKET STATISTICS
Base Year [2023] USD 998.82 million
Estimated Year [2024] USD 1,137.75 million
Forecast Year [2030] USD 2,542.11 million
CAGR (%) 14.27%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Doose Syndrome Market

The Doose Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Government and non-profit organization initiatives to support research and patient care for rare diseases
    • Adoption of personalized medicine approaches improving patient outcomes in the management of Doose syndrome
    • Collaboration between pharmaceutical companies and research institutions to develop targeted therapies for Doose syndrome
    • Increased funding for clinical trials focusing on rare epileptic conditions promoting new drug discoveries
  • Market Restraints
    • Strict regulatory requirements and lengthy approval processes for new therapies for Doose syndrome hindering faster market entry
    • Lack of comprehensive awareness and education programs about Doose syndrome among primary care physicians and the general public impairing early diagnosis and treatment
  • Market Opportunities
    • Establishing specialized patient support services and resources for families affected by Doose syndrome
    • Developing a comprehensive digital platform for tracking and monitoring Doose syndrome symptoms and treatment
    • Partnering with healthcare providers to integrate Doose syndrome treatment protocols into standard care practices
  • Market Challenges
    • High cost of treatment and limited insurance coverage for Doose Syndrome management reducing accessibility for many families
    • Challenges in conducting research and clinical trials for rare diseases like Doose Syndrome leading to slower development of new therapies

Porter's Five Forces: A Strategic Tool for Navigating the Doose Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Doose Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Doose Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Doose Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Doose Syndrome Market

A detailed market share analysis in the Doose Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Doose Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Doose Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Doose Syndrome Market

A strategic analysis of the Doose Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Doose Syndrome Market, highlighting leading vendors and their innovative profiles. These include BioMarin Pharmaceutical, Cerecor, Eisai Co., Greenwich Biosciences, GW Pharmaceuticals, INSYS Therapeutics, Johnson & Johnson, Lundbeck, Marinus Pharmaceuticals, Neurelis, Ovid Therapeutics, Pfizer, PTC Therapeutics, Purdue Pharma, Sanofi, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical Company Limited, Upsher-Smith Laboratories, and Zogenix.

Market Segmentation & Coverage

This research report categorizes the Doose Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Ketogenic Diet and Vagus Nerve Stimulation. The Pharmacological Treatments is further studied across Antiepileptic Drugs, Cannabidiol Products, Corticosteroids, and Immunoglobulins.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Government and non-profit organization initiatives to support research and patient care for rare diseases
      • 5.1.1.2. Adoption of personalized medicine approaches improving patient outcomes in the management of Doose syndrome
      • 5.1.1.3. Collaboration between pharmaceutical companies and research institutions to develop targeted therapies for Doose syndrome
      • 5.1.1.4. Increased funding for clinical trials focusing on rare epileptic conditions promoting new drug discoveries
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory requirements and lengthy approval processes for new therapies for Doose syndrome hindering faster market entry
      • 5.1.2.2. Lack of comprehensive awareness and education programs about Doose syndrome among primary care physicians and the general public impairing early diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Establishing specialized patient support services and resources for families affected by Doose syndrome
      • 5.1.3.2. Developing a comprehensive digital platform for tracking and monitoring Doose syndrome symptoms and treatment
      • 5.1.3.3. Partnering with healthcare providers to integrate Doose syndrome treatment protocols into standard care practices
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of treatment and limited insurance coverage for Doose Syndrome management reducing accessibility for many families
      • 5.1.4.2. Challenges in conducting research and clinical trials for rare diseases like Doose Syndrome leading to slower development of new therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Application of non-pharmacological treatment in doose syndrome treatment for pediatric patient
    • 5.2.2. Distribution channel: Utilization of retail pharmacies for chronic and acute phase of doose syndrome
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Doose Syndrome Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Ketogenic Diet
    • 6.2.2. Vagus Nerve Stimulation
  • 6.3. Pharmacological Treatments
    • 6.3.1. Antiepileptic Drugs
    • 6.3.2. Cannabidiol Products
    • 6.3.3. Corticosteroids
    • 6.3.4. Immunoglobulins

7. Doose Syndrome Market, by Distribution Channels

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Doose Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Doose Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Doose Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Jazz Pharmaceuticals launches phase 3 trial of epidiolex for doose syndrome, aiming to reduce seizures and expand market presence
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BioMarin Pharmaceutical
  • 2. Cerecor
  • 3. Eisai Co.
  • 4. Greenwich Biosciences
  • 5. GW Pharmaceuticals
  • 6. INSYS Therapeutics
  • 7. Johnson & Johnson
  • 8. Lundbeck
  • 9. Marinus Pharmaceuticals
  • 10. Neurelis
  • 11. Ovid Therapeutics
  • 12. Pfizer
  • 13. PTC Therapeutics
  • 14. Purdue Pharma
  • 15. Sanofi
  • 16. Sunovion Pharmaceuticals
  • 17. Supernus Pharmaceuticals
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Upsher-Smith Laboratories
  • 20. Zogenix

LIST OF FIGURES

  • FIGURE 1. DOOSE SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DOOSE SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DOOSE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DOOSE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DOOSE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DOOSE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DOOSE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DOOSE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DOOSE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DOOSE SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DOOSE SYNDROME MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DOOSE SYNDROME MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DOOSE SYNDROME MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DOOSE SYNDROME MARKET SIZE, BY CANNABIDIOL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DOOSE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DOOSE SYNDROME MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DOOSE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DOOSE SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DOOSE SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DOOSE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DOOSE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DOOSE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 190. DOOSE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DOOSE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023